Researchers conducted a multicenter trial to compare two different devices used to treat non-valvular atrial fibrillation. The study focused on patients who were at high risk of suffering an ischemic stroke. They compared the AnchorMan LAA closure device against the Watchman 2.5 device.
The results showed that both devices performed equally well over a 12 month period. Both the AnchorMan and the Watchman achieved a 98.1% success rate in keeping patients free from stroke, blood clots, and other major cardiovascular events. Additionally, both devices were successful at closing the left atrial appendage.
Safety data showed that rates of death, stroke, and major bleeding were low and similar for both groups. However, it is important to note that this was an open-label trial, which means the researchers knew which device each patient received. Because this study is relatively small with 216 participants, patients should talk to their doctor to decide which device is best for their specific needs.
